摘要
目的:探讨生长激素治疗儿童特发性矮小症(ISS)对成年终身高的改善情况。方法:回顾性分析已确诊为ISS并使用生长激素治疗,且目前已达到成年终身高的86例患儿,其中男50例,女36例。根据用药时间分为长疗程组(≥1年) 65例和短疗程组(<1年) 21例。观察患儿身高标准差积分(HSDS)、基线身高标准差积分(BHSDS)、遗传靶身高(TH)、遗传靶身高标准差积分(THSDS)、接近成年终身高(NAH)、接近成年终身高标准差积分(NAHSDS)等指标。结果:长疗程组患儿NAHSDS大于短疗程组(P<0. 05);长疗程组患儿NAHSDS大于THSDS(P<0. 05);短疗程组患儿NAHSDS小于THSDS(P<0. 05); 75. 6%(65/86)的患儿最终身高达到正常身高,其中长疗程组中95. 2%患儿最终身高达到正常身高。结论:使用生长激素治疗ISS患儿,长疗程(≥1年)较适宜。
Objective:To probe into the improvement of growth hormone on near-adult height of children with idiopathic short stature(ISS).Methods:Retrospective analysis was performed on 86 children diagnosed with ISS and treated with growth hormone,who had reached the near-adult height,including 50 males and 36 females.According to the duration of medication,there were 65 patients in the long course group(≥1 year)and 21 patients in the short course group(<1 year).Height standard deviation scores(HSDS),baseline height standard deviation scores(BHSDS),genetic target height(TH),genetic target height standard deviation scores(THSDS),near-adult height(NAH),near-adult height standard deviation scores(NAHSDS)and other indicators of two groups were observed.Results:NAHSDS of the long course group was greater than that of the short course group(P<0.05).NAHSDS was greater than THSDS in the long course group(P<0.05).NAHSDS of short course group was less than THSDS(P<0.05).A total of 75.6%(65/86)of the children eventually reached the normal height,and 95.2%of the children in the long treatment group eventually reached the normal height.Conclusion:To set the course of treatment≥1 year in children with ISS with growth hormone therapy is suitable.
作者
陈倩
杨亭
张萱
程茜
Chen Qian;Yang Ting;Zhang Xuan;Cheng Qian(Children's Hospital of Chongqing Medical University,Chongqing Key Laboratory of Child Nutrition and Health,Ministry of Education Key Laboratory of Child Development and Disorders,China International Science and Technology Cooperation Base of Child Development and Critical Disorders,Chongqing Key Laboratory of Pediatrics,Chongqing 400014,China)
出处
《儿科药学杂志》
CAS
2019年第6期6-9,共4页
Journal of Pediatric Pharmacy
基金
重庆市卫生局科研计划面上项目
编号2013-2-054
